S M Helfgott
Index: Semin. Arthritis Rheum. 23(5) , 341-6, (1994)
Full Text: HTML
Nonsteroidal antiinflammatory drugs (NSAIDs) have long been used as therapy for arthritis patients. However, in some patients these drugs can cause gastrointestinal hemorrhage, perforation, or ulcer through direct topical effects, enterohepatic recirculation, and systemic effects. In an effort to address this problem, new NSAIDs have been developed. Nabumetone, which belongs to a new class of NSAID, is a nonacidic agent that has been associated with a low incidence of peptic ulcer. This article examines available clinical data on nabumetone, including studies on gastrointestinal safety and effectiveness in osteoarthritis and rheumatoid arthritis patients, and data that may provide an explanation for nabumetone's low incidence of ulceration.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Nabumetone
CAS:42924-53-8 |
C15H16O2 |
|
Exploration of alternate catalytic mechanisms and optimizati...
2014-01-09 [J. Mol. Biol. 426(1) , 256-71, (2014)] |
|
Hypersensitivity to nabumetone: cross reactivity with naprox...
2013-07-01 [Ann. Allergy Asthma Immunol. 111(1) , 74-5, (2013)] |
|
Effects of nabumetone and dipyrone on experimentally induced...
2013-04-01 [Inflammation 36(2) , 476-81, (2013)] |
|
A review of analytical techniques for determination of oxica...
2009-01-15 [Talanta 77(3) , 925-42, (2009)] |
|
[Rationale for using nabumetone and clinical experience].
2000-01-01 [Drugs 59 Spec No 1 , 35-41, (2000)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
